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Serial passage of Cryptococcus neoformans in mice increases virulence relative to the nonpassaged line. 
Postpassaged lines showed no difference in the expression of most known virulence factors, with the exception 
that the more virulent lines had smaller capsules in vitro. These data imply that other mechanisms of virulence 
remain to be discovered.
One approach to study the evolution of virulence experi­
mentally is to serially passage a microbe in a host (8) and then 
compare the pre- and postpassaged lines to identify traits that 
affect changes in virulence. The yeast Ciyptococcus neoformans 
is commonly found in the environment and causes disease 
primarily in immunocompromised humans. Its best-recognized 
virulence factors are the capsule (1, 14), melanin production 
(15, 25), laccase (17, 22), phospholipase (5), urease (6), and 
growth rate (18). Passage of C  neoformans in BIO major his­
tocompatibility complex-congenic mice and BALB/c mice in­
creased virulence relative to the nonpassaged line, using time 
to death as the measure of virulence (19). These observations 
prompted this study to investigate the mechanism responsible 
for the virulence increase.
The C  neoformans lines used in this study were derived by 
serial passage in mice and are described in detail in reference 
19. Capsule size in vitro was measured as described in refer­
ence 26. Capsule size in vivo was measured from frozen brain 
and liver homogenates scraped into a microcentrifuge tube, 
washed once with 100 |xl phosphate-buffered saline, resus­
pended in 10 |xl phosphate-buffered saline, and measured as 
described in reference 26. To determine if the lines differed in 
their ability to release capsular glucuronoxylomannan (GXM) 
into the medium, capsules were induced in DM E (as for mea­
suring capsule size) and the concentration of GXM in the 
supernatant was measured the next day by capture enzyme- 
linked immunosorbent assay as described previously (2).
Melanization was assessed qualitatively by colony color on 
L-dopa plates after incubation at 30°C for 3, 5, and 7 days. The 
amount of color produced was scored based on colony photo­
graphs using a 0 to 5 scale, with 0 being white and 5 corre­
sponding to black. Laccase activity was measured as described 
previously (13). Extracellular phospholipase activity was deter­
mined as described previously (9). Urease activity was deter­
mined as described previously (16).
All lines were grown in yeast-peptone-dextrose medium at 
37°C overnight and then diluted in 10 ml yeast-peptone-dex- 
trose medium and the growth rate measured as described pre­
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viously (10) from CFU and turbidity. CFU were measured 
three times (every 4 h). The doubling time was calculated using 
the following formula: time x  {0.693/[ln(final OD/initial 
OD)]}, in which OD is the optical density.
The phagocytic efficacy of the macrophage-like cell line 
J774.16 was measured by the method used in reference 24, with 
minor modifications. Macrophage killing was measured by the 
method used in reference 12, with modifications. Briefly, 
J774.16 cells were opsonized with either 10% guinea pig serum 
or 10 [Ag/ml of the monoclonal antibody I8B7. Postpassaged 
lines and macrophages were incubated in a 1:1 ratio for 4- and 
18-h intervals, and viability was assessed by trypan blue exclu­
sion.
A logistic correlation was used to test if virulence factors 
were correlated with time to death (virulence) during the last 
passage. A standard least-squares test with simple contrasts 
was used to test for significant differences between nonpas­
saged and postpassaged C  neoformans macrophage killing.
Surprisingly, there was no correlation between time to death 
and the following line characteristics: capsule GXM release in 
vitro, secreted extracellular laccase, extracellular phospho­
lipase secretion, urease activity, growth rates, and in vitro 
phagocytosis with mouse intraperitoneal macrophages (Table 
I). There was also no significant difference in macrophage 
killing between the nonpassaged H99 and any postpassaged 
line (Table I). Furthermore, there was no correlation between 
the amount of melanization and the time to death (Table I). 
Eight of the 14 C  neoformans passaged lines produced some 
melanin by day 7, but only 5 of those 8 produced a significant 
amount of melanin by day 7 (Table I). There was no correla­
tion between capsule size in the brain or liver of moribund 
mice and passage time to death (Table I). However, a negative 
correlation between capsule size in vitro and passage time to 
death (virulence) was found (P = 0.0347, R2 = 0.28) (Table I). 
All but one ( F J  of the passaged C  neoformans lines produced 
a capsule smaller than the capsule of the nonpassaged H99 
(Fig. I) in vitro.
There was a statistically significant negative correlation be­
tween increased virulence (decreased time to death) and 
smaller capsule size in vitro (P  = 0.0347) that is opposite that 
of conventional views on capsule size and virulence. This ob­
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FIG. 1. Correlation between capsule size and passage time to 
death. Points are the average in vitro capsule size of each line plotted 
against passage time to death. Strain names indicate the MHC geno­
type or strain of mice in which C. neofonnans was passaged (19).
passaged lines had higher GXM scrum levels (data not shown), 
suggests that increased virulcncc was due cither to more in vivo 
capsulc shedding or to an increased growth rate in vivo. Sincc 
soluble capsular polysaccharidc can mediate many deleterious 
cffccts on the immune system, including alteration in cytokinc 
regulation (21, 23), intcrfcrcncc with lcukocytc migration (7), 
and apoptosis (4), the finding of smaller capsulcs and increased 
scrum polysaccharidc suggests a potential explanation in addi­
tion to increased growth rate in vivo, for the increased viru­
lcncc of the highly virulent mouse-passaged lines.
Growth rate/doubling time was tested in vitro in different 
media, but no correlation with time to death was found. We 
did not measure growth rate in vivo bccausc that would require 
separating differences in replication rate from changcs in tissue 
burden as a result of clcarancc by immune cclls. Sincc in­
creased growth rate in vivo may still be a possible mcchanism 
for the increased virulcncc seen in these mouse-passaged lines 
of C. neoformans, wc cannot cxcludc this mcchanism.
From a microbc-ccntric perspective, there arc several po­
tential explanations for these observations. First, the virulcncc 
factors that remained unchanged in postpassagc lines may 
function in a qualitative manner such that only their presence 
is required for virulcncc. The fact that quantitative differences 
in virulcncc factor expression have not been associated with 
virulcncc in C. neoformans supports this view. Second, mouse 
passage may not affcct essential fungal characteristics that 
arose in the environment and function as virulcncc factors in 
mammals. In this regard, wc note that the capsulc of C. neo­
form ans seldom elicits high-titcr or protective antibody re­
sponses in natural infections (3, 20), and consequently, this 
trait may not be under strong immune selection pressure. Sim­
ilarly, murine infection docs not clicit antibodies to laccasc 
(I I). Third, line adaptation to survival in micc may involve 
selection for other virulcncc factors.
In conclusion, mouse passage can increase the virulcncc of
C. neoformans without selecting for significant differences in 
many wcll-charactcrizcd virulcncc factors. The increased viru­
lcncc seen in the highly virulent lines may be due to a combi­
nation of increased growth rate in vivo, increased scrum cap­
sular polysaccharidc, or changcs in undiscovered virulcncc 
factors.
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